Leukemia, Myelocytic, Acute
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that HDAC inhibitors will be promising therapeutic drugs for MDS and AML with ASXL1 and SETBP1 mutations.
|
30367089 |
2018 |
Leukemia, Myelocytic, Acute
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
A total of 1.2% (3/249) of AML and 1.8% (2/114) of MDS patients were found with heterozygous SETBP1 mutations.
|
29549983 |
2018 |
Leukemia, Myelocytic, Acute
|
0.590 |
Biomarker
|
disease |
BEFREE |
In general, somatic SETBP1 mutations have a significant clinical impact on the outcome as poor prognostic factor, due to downstream HOXA-pathway as well as associated aggressive types of chromosomal defects (-7/del(7q) and i(17q)), which is consistent with wild-type SETBP1 activation in aggressive types of acute myeloid leukemia and leukemic evolution.
|
28447248 |
2017 |
Leukemia, Myelocytic, Acute
|
0.590 |
Biomarker
|
disease |
BEFREE |
SETBP1-MT collaborated with ASXL1-MT in inducing acute myeloid leukemia in vivo.
|
25306901 |
2015 |
Leukemia, Myelocytic, Acute
|
0.590 |
Biomarker
|
disease |
BEFREE |
We assessed the frequency and clinicopathologic significance of 19 genes currently identified as significantly mutated in myeloid neoplasms, RUNX1, ASXL1, TET2, CEBPA, IDH1, IDH2, DNMT3A, FLT3, NPM1, TP53, NRAS, EZH2, CBL, U2AF1, SF3B1, SRSF2, JAK2, CSF3R, and SETBP1, across 93 cases of acute myeloid leukemia (AML) using capture target enrichment and next-generation sequencing.
|
25412851 |
2015 |
Leukemia, Myelocytic, Acute
|
0.590 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
|
23889083 |
2013 |
Leukemia, Myelocytic, Acute
|
0.590 |
GeneticVariation
|
disease |
UNIPROT |
SETBP1 mutation analysis in 944 patients with MDS and AML.
|
23648668 |
2013 |
Leukemia, Myelocytic, Acute
|
0.590 |
Biomarker
|
disease |
BEFREE |
Recent studies have identified recurrent mutations in SETBP1, the gene that encodes SET-binding protein 1, in several types of myeloid malignancies, including chronic myeloid and acute myeloid leukemias.
|
23892662 |
2013 |
Leukemia, Myelocytic, Acute
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
In this study, we describe a PMF case evolved to AML with a t(12;18)(p13;q12) rearrangement showing the downregulation of the intronic miR_4319 and the overexpression of its host gene, SET binding protein (SETBP1).
|
22873195 |
2012 |
Leukemia, Myelocytic, Acute
|
0.590 |
AlteredExpression
|
disease |
BEFREE |
In addition, we found that either deregulated expression of the endogenous PP2A inhibitors SET or CIP2A, overexpression of SETBP1, or downregulation of some PP2A subunits, might be contributing to PP2A inhibition in AML.
|
21233840 |
2011 |
Leukemia, Myelocytic, Acute
|
0.590 |
AlteredExpression
|
disease |
BEFREE |
In summary, our data show a novel leukemogenic mechanism through SETBP1 overexpression; moreover, multivariate analysis confirms the negative prognostic impact of SETBP1 overexpression in AML, especially in elderly patients, where it could be used as a predictive factor in any future clinical trials with PP2A activators.
|
19965692 |
2010 |
Leukemia, Myelocytic, Acute
|
0.590 |
CausalMutation
|
disease |
CGI |
|
|
|